Core Viewpoint - Rezolute, Inc. has announced an underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $90 million for research and development, general corporate expenses, and working capital needs [1][4]. Group 1: Offering Details - The offering consists of 20,786,923 shares of common stock priced at $3.25 per share and pre-funded warrants to purchase up to 6,905,385 shares at $3.2490 each [1]. - Gross proceeds from the offering are expected to be around $90 million before deducting underwriting discounts and commissions [1]. - The underwriters have a 30-day option to purchase an additional 4,153,846 shares at the offering price [1]. Group 2: Investor Participation - The offering includes participation from both new and existing investors, such as Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and others [3]. Group 3: Management and Advisors - Guggenheim Securities is the sole book-running manager for the offering, with BTIG, H.C. Wainwright & Co., and Jones acting as lead managers [4]. - Craig-Hallum and Maxim Group LLC are co-managers, while WG Partners LLP serves as the financial advisor [4]. Group 4: Company Overview - Rezolute, Inc. is a late-stage biopharmaceutical company focused on developing therapies for serious rare diseases, particularly targeting hypoglycemia caused by hyperinsulinism [7]. - The company's antibody therapy, ersodetug, has shown significant benefits in clinical trials for treating congenital and tumor-related hyperinsulinism [7].
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants